159 related articles for article (PubMed ID: 9182836)
41. [The effect of induction chemotherapy with CBDCA, 5-FU and UFT in head and neck cancer].
Homma A; Iizuka K; Nakamaru Y; Yonekawa H
Gan To Kagaku Ryoho; 1994 Apr; 21(5):627-31. PubMed ID: 8154888
[TBL] [Abstract][Full Text] [Related]
42. Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule.
Schilder RJ; LaCreta FP; Perez RP; Johnson SW; Brennan JM; Rogatko A; Nash S; McAleer C; Hamilton TC; Roby D
Cancer Res; 1994 Feb; 54(3):709-17. PubMed ID: 8306332
[TBL] [Abstract][Full Text] [Related]
43. Prediction of hematologic toxicity of carboplatin by creatinine clearance rate.
Taguchi J; Saijo N; Miura K; Shinkai T; Eguchi K; Sasaki Y; Tamura T; Sakurai M; Minato K; Fujiwara Y
Jpn J Cancer Res; 1987 Sep; 78(9):977-82. PubMed ID: 3117753
[TBL] [Abstract][Full Text] [Related]
44. [Pharmacokinetics of carboplatin after intraperitoneal administration and clinical effect in ovarian cancer].
Ohno M; Hirokawa M; Hando T
Gan To Kagaku Ryoho; 1992 Dec; 19(14):2355-61. PubMed ID: 1463342
[TBL] [Abstract][Full Text] [Related]
45. Pharmacokinetic and phase I evaluation of carboplatin in dogs.
Page RL; McEntee MC; George SL; Williams PL; Heidner GL; Novotney CA; Riviere JE; Dewhirst MW; Thrall DE
J Vet Intern Med; 1993; 7(4):235-40. PubMed ID: 8246213
[TBL] [Abstract][Full Text] [Related]
46. Comparison of methods for the estimation of carboplatin pharmacokinetics in paediatric cancer patients.
Peng B; Boddy AV; Cole M; Pearson AD; Chatelut E; Rubie H; Newell DR
Eur J Cancer; 1995 Oct; 31A(11):1804-10. PubMed ID: 8541105
[TBL] [Abstract][Full Text] [Related]
47. A phase I and pharmacologic study of pyrazoloacridine (NSC 366140) and carboplatin in patients with advanced cancer.
Adjei AA; Reid JM; Erlichman C; Sloan JA; Pitot HC; Alberts SR; Goldberg RM; Hanson LJ; Ruben S; Boemer SA; Atherton P; Ames MM; Kaufmann SH
Invest New Drugs; 2002 Aug; 20(3):297-304. PubMed ID: 12201492
[TBL] [Abstract][Full Text] [Related]
48. A limited-sampling method for evaluation of the area under the curve of ultrafilterable carboplatin in children.
Doz F; Urien S; Chatelut E; Michon J; Rubie H; Zucker JM; Canal P; Bastian G
Cancer Chemother Pharmacol; 1998; 42(3):250-4. PubMed ID: 9685062
[TBL] [Abstract][Full Text] [Related]
49. Carboplatin and cisplatin pharmacokinetics after intrapleural combination treatment in patients with malignant pleural effusion.
Lerza R; Vannozzi MO; Tolino G; Viale M; Bottino GB; Bogliolo G; Cerruti A; Castello G; Mencoboni M; Reggiardo G; Pannacciulli I; Esposito M
Ann Oncol; 1997 Apr; 8(4):385-91. PubMed ID: 9209670
[TBL] [Abstract][Full Text] [Related]
50. Digitonin enhances the efficacy of carboplatin in liver tumour after intra-arterial administration.
Lindnér PG; Heath D; Howell SB; Naredi PL; Hafström LR
Cancer Chemother Pharmacol; 1997; 40(5):444-8. PubMed ID: 9272123
[TBL] [Abstract][Full Text] [Related]
51. Clinical trial and pharmacokinetics of carboplatin 560 mg/m2 in children.
Doz F; Brugières L; Bastian G; Quintana E; Lemerle J; Zucker JM
Med Pediatr Oncol; 1990; 18(6):459-65. PubMed ID: 2233516
[TBL] [Abstract][Full Text] [Related]
52. Weekly dosing of carboplatin increases risk of allergy in children.
Yu DY; Dahl GV; Shames RS; Fisher PG
J Pediatr Hematol Oncol; 2001; 23(6):349-52. PubMed ID: 11563768
[TBL] [Abstract][Full Text] [Related]
53. Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer.
Jodrell DI; Reyno LM; Sridhara R; Eisenberger MA; Tkaczuk KH; Zuhowski EG; Sinibaldi VJ; Novak MJ; Egorin MJ
J Clin Oncol; 1994 Jan; 12(1):166-75. PubMed ID: 8270974
[TBL] [Abstract][Full Text] [Related]
54. Infusional carboplatin. Phase I studies of 5-day and 14-day infusions.
Lokich J; Anderson N; Bern M; Zipli T; Gonsalves L; Moore C
Cancer; 1991 Jul; 68(1):68-71. PubMed ID: 2049755
[TBL] [Abstract][Full Text] [Related]
55. Pharmacokinetics of etoposide and carboplatin in cerebrospinal fluid and plasma during hyperosmotic disruption of the blood brain barrier and intraarterial combination chemotherapy.
Morikawa N; Mori T; Abe T; Kawashima H; Takeyama M; Hori S
Biol Pharm Bull; 1999 Apr; 22(4):428-31. PubMed ID: 10328568
[TBL] [Abstract][Full Text] [Related]
56. A single-sample assay for the estimation of the area under the free carboplatin plasma concentration versus time curve.
Ghazal-Aswad S; Calvert AH; Newell DR
Cancer Chemother Pharmacol; 1996; 37(5):429-34. PubMed ID: 8599865
[TBL] [Abstract][Full Text] [Related]
57. Therapeutic Drug Monitoring of Carboplatin in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors: Pharmacokinetic Results of a Phase II Multicenter Study.
Moeung S; Chevreau C; Broutin S; Guitton J; Lelièvre B; Ciccolini J; Massart C; Fléchon A; Delva R; Gravis G; Lotz JP; Bay JO; Gross-Goupil M; Paci A; Marsili S; Malard L; Chatelut E; Thomas F
Clin Cancer Res; 2017 Dec; 23(23):7171-7179. PubMed ID: 28928162
[No Abstract] [Full Text] [Related]
58. Pharmacokinetics of Carboplatin in a One-Year-Old Anuric Boy Undergoing Hemodialysis and a Review of the Literature.
Kamei K; Sako M; Ishikawa T; Sato M; Ogura M; Uno T; Kiyotani C; Mori T; Tanaka H; Ito S; Nakamura H
Ther Apher Dial; 2015 Oct; 19(5):491-6. PubMed ID: 25916242
[TBL] [Abstract][Full Text] [Related]
59. Validation of a limited sampling model for carboplatin in a high-dose chemotherapy combination.
van Warmerdam LJ; Rodenhuis S; van Tellingen O; Maes RA; Beijnen JH
Cancer Chemother Pharmacol; 1994; 35(2):179-81. PubMed ID: 7987998
[TBL] [Abstract][Full Text] [Related]
60. Effect of whole body hyperthermia on carboplatin disposition and toxicity in dogs.
Page RL; McEntee MC; Williams PL; George SL; Price GS; Novotney CA; Hauck ML; Riviere JE; Dewhirst MW; Thrall DE
Int J Hyperthermia; 1994; 10(6):807-16. PubMed ID: 7884240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
